MediPost "Expanding Open Innovation, Launching Commercialization of Core Technologies"

Exterior view of Medipost headquarters in Pangyo.

[Asia Economy Reporter Lee Gwan-joo] Medipost is expanding its "open innovation" strategy and actively engaging in joint development with bio companies that possess technologies capable of creating synergy effects.

On the 27th, Medipost announced that through its in-house Innovation Research Team, it is continuously discovering creative partners in next-generation stem cell platforms, exosome therapeutics, and more.

Earlier in May, Medipost declared its entry into the cell and gene therapy CDMO (Contract Development and Manufacturing Organization) market, signaling an expansion of its business scale through new ventures. The company explained that the expansion of open innovation aligns with this strategy.

The company is currently seeking bio companies that can create synergy with its core technology, SMUP-Cell. SMUP-Cell is a platform that selects high-efficacy stem cells and reduces production time through large-scale cultivation and automated harvesting, thereby lowering production costs and improving quality control. Additionally, it has been developed in a frozen formulation, addressing transportation and storage issues that were limitations of existing stem cell therapies.

Medipost first introduced the injectable osteoarthritis treatment "SMUP-IA-01" applying SMUP-Cell technology and is conducting Phase 2 clinical trials domestically. Furthermore, the SMUP-Cell platform is expected to expand into various bio fields such as ▲production of original cell lines for cell and gene therapies ▲development of immune cell therapies ▲delivery systems for biological preparations ▲therapeutics based on stem cell-derived substances.

The joint development of exosome therapeutics also took its first step in April this year. Medipost signed a joint research agreement with ExosomePlus, a company developing new drugs based on exosomes, to develop disease therapeutics derived from stem cell-based exosomes. It is also collaborating with related companies to develop research models using gene-editing technology to enhance stem cell efficacy and organoids, which are similar to organs.

A Medipost official stated, "To launch biopharmaceuticals in the global market, collaboration with leading bio companies in various fields is essential," adding, "We will strive to rapidly bring biopharmaceuticals applying Medipost’s core original technologies to the global market through joint development with companies or research organizations possessing global technological competitiveness."

This content was produced with the assistance of AI translation services.